|
|
|
|
|
|
|
|
|
|
medical news
June 05, 2016
CHICAGO — More transparency regarding the costs of various treatment regimens in real time is needed to "choose wisely" for patients, providers, and payers, said Rena M. Conti, PhD, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.
In a presentation on value in cancer care, Dr Conti, associate professor and an economist at the University of Chicago, discussed 3 posters presented this year at the ASCO Annual Meeting.1 The first was a global cost-effectiveness analysis of first-line bevacizumab in metastatic colorectal cancer from the perspective of payers in the United States, United Kingdom, Canada, Australia, and Israel.2....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.